# Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease

> **NCT02164604** · NA · COMPLETED · sponsor: **Kantonsspital Aarau** · enrollment: 6 (actual)

## Conditions studied

- Retinopathy of Prematurity

## Interventions

- **DRUG:** intravitreal injection of 0.03ml ranibizumab

## Key facts

- **NCT ID:** NCT02164604
- **Lead sponsor:** Kantonsspital Aarau
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02164604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02164604, "Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02164604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*